New heart failure drug gets first human safety test

NCT ID NCT07218627

Recruiting now Symptom relief Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug called NNC0537-1482 in 36 adults with heart failure. The main goal is to check if the drug is safe and how the body handles it. Participants will receive either the drug or a placebo by injection, and neither they nor the doctors will know which they got. The study lasts up to 64 days and focuses on side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NNC0537-1482
What this could lead to: If this early trial shows the drug is safe, it could point toward a new treatment option for heart failure that eases symptoms.
What could go wrong: This is a very early, small Phase 1 study with only 36 people. The main goal is safety, not effectiveness, so it may not lead to a working treatment. Side effects are possible and unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Richmond Pharmacology
RECRUITING

London, SE1 1YR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.